Rick Bangs

2.5k total citations
31 papers, 382 citations indexed

About

Rick Bangs is a scholar working on Surgery, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Rick Bangs has authored 31 papers receiving a total of 382 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Surgery, 7 papers in Oncology and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Rick Bangs's work include Bladder and Urothelial Cancer Treatments (24 papers), Urinary and Genital Oncology Studies (11 papers) and Esophageal Cancer Research and Treatment (7 papers). Rick Bangs is often cited by papers focused on Bladder and Urothelial Cancer Treatments (24 papers), Urinary and Genital Oncology Studies (11 papers) and Esophageal Cancer Research and Treatment (7 papers). Rick Bangs collaborates with scholars based in United States, Canada and Italy. Rick Bangs's co-authors include Seth P. Lerner, Catherine M. Tangen, Melissa Plets, Ian M. Thompson, Scott D. Ramsey, David J. McConkey, Matthew I. Milowsky, M. Scott Lucia, Ajjai Alva and Wassim Kassouf and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Rick Bangs

28 papers receiving 379 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rick Bangs United States	11	251	89	83	82	54	31	382
Ravi Kannan India	10	198 0.8×	71 0.8×	31 0.4×	80 1.0×	31 0.6×	31	326
Karl H. Tully Germany	10	156 0.6×	96 1.1×	95 1.1×	40 0.5×	30 0.6×	46	303
Deborah Enting United Kingdom	9	203 0.8×	167 1.9×	87 1.0×	23 0.3×	74 1.4×	42	374
Rachel Jia United States	10	150 0.6×	87 1.0×	61 0.7×	19 0.2×	27 0.5×	16	256
James Hok‐Leung Tsu China	10	143 0.6×	45 0.5×	169 2.0×	45 0.5×	32 0.6×	29	311
Suzanne B. Merrill United States	9	257 1.0×	80 0.9×	107 1.3×	31 0.4×	77 1.4×	30	319
Andrew Rothman United States	8	275 1.1×	93 1.0×	114 1.4×	85 1.0×	24 0.4×	12	404
Kelly K. Bree United States	12	244 1.0×	44 0.5×	61 0.7×	85 1.0×	50 0.9×	43	341
Edward Schervish United States	8	204 0.8×	24 0.3×	114 1.4×	31 0.4×	95 1.8×	16	308
Sultan S. Alkhateeb Saudi Arabia	9	303 1.2×	96 1.1×	83 1.0×	72 0.9×	85 1.6×	17	393

Countries citing papers authored by Rick Bangs

Since Specialization

Citations

This map shows the geographic impact of Rick Bangs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rick Bangs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rick Bangs more than expected).

Fields of papers citing papers by Rick Bangs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rick Bangs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rick Bangs. The network helps show where Rick Bangs may publish in the future.

Co-authorship network of co-authors of Rick Bangs

This figure shows the co-authorship network connecting the top 25 collaborators of Rick Bangs. A scholar is included among the top collaborators of Rick Bangs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rick Bangs. Rick Bangs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sadeghi, Sarmad, Primo N. Lara, Stephanie Berg, et al.. (2025). A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.. Journal of Clinical Oncology. 43(5_suppl).

Apolo, Andrea B., Di Jiang, Eila C. Skinner, et al.. (2025). Understanding patient perspectives in the management of their muscle‐invasive bladder cancer. British Journal of Urology. 136(3). 493–499.

Loriot, Yohann, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.. (2024). A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer. Future Oncology. 20(23). 1621–1631. 1 indexed citations

Graboyes, Evan M., Simon J. Craddock Lee, Stacy Tessler Lindau, et al.. (2024). Interventions addressing health-related social needs among patients with cancer. JNCI Journal of the National Cancer Institute. 116(4). 497–505. 9 indexed citations

Plets, Melissa, Peter C. Black, Parminder Singh, et al.. (2024). Correlation of urinary comprehensive genomic profile with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605.. Journal of Clinical Oncology. 42(4_suppl). 529–529.

Lerner, Seth P., Catherine M. Tangen, Robert S. Svatek, et al.. (2024). Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. New England Journal of Medicine. 391(13). 1206–1216. 18 indexed citations

Black, Peter C., Catherine M. Tangen, Parminder Singh, et al.. (2023). Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605. European Urology. 84(6). 536–544. 48 indexed citations

Mossanen, Matthew, Angela B. Smith, Richard S. Matulewicz, et al.. (2023). Bladder cancer patient and provider perspectives on smoking cessation. Urologic Oncology Seminars and Original Investigations. 41(11). 457.e9–457.e16. 3 indexed citations

Lerner, Seth P., David J. McConkey, Catherine M. Tangen, et al.. (2023). Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Clinical Cancer Research. 30(2). 444–449. 9 indexed citations

10.

Flaig, Thomas W., Catherine M. Tangen, Siamak Daneshmand, et al.. (2023). Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). European Urology. 84(3). 341–347. 9 indexed citations

11.

Necchi, Andrea, Monika Joshi, Rick Bangs, et al.. (2022). Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly. Clinical Genitourinary Cancer. 21(2). 301–308. 1 indexed citations

12.

Bangs, Rick, et al.. (2022). Improving Patient Advocacy in NCI Scientific Steering Committees and Task Forces. JNCI Journal of the National Cancer Institute. 114(8). 1059–1064. 2 indexed citations

13.

Flaig, Thomas W., Catherine M. Tangen, Siamak Daneshmand, et al.. (2022). SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up.. Journal of Clinical Oncology. 40(6_suppl). 536–536. 5 indexed citations

14.

Sonpavde, Guru, Melissa Plets, Michael A. Liss, et al.. (2022). Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011).. Journal of Clinical Oncology. 40(6_suppl). TPS591–TPS591. 1 indexed citations

15.

Flaig, Thomas W., Catherine M. Tangen, Siamak Daneshmand, et al.. (2021). A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clinical Cancer Research. 27(9). 2435–2441. 58 indexed citations

16.

Hahn, Noah M., David A. Schulman, Frank A. Sloan, et al.. (2021). Patient, caregiver, and provider reported risk-benefit acceptance thresholds in non-muscle invasive bladder cancer (NMIBC) trial designs.. Journal of Clinical Oncology. 39(6_suppl). 424–424. 1 indexed citations

17.

Bangs, Rick & Tony Crispino. (2018). From the other side: The patient perspective on cancer clinical trials. Urologic Oncology Seminars and Original Investigations. 37(5). 331–335. 2 indexed citations

18.

Smith, Angela B., et al.. (2018). Patient‐centered prioritization of bladder cancer research. Cancer. 124(15). 3136–3144. 34 indexed citations

19.

Quale, Diane Zipursky, et al.. (2015). Bladder Cancer Patient Advocacy: A Global Perspective. Bladder Cancer. 1(2). 117–122. 7 indexed citations

20.

Lerner, Seth P., Hongli Li, Robert S. Svatek, et al.. (2014). Prerandomization factors and utilization of neoadjuvant chemotherapy in a clinical trial of extended versus standard pelvic lymphadenectomy at the time of radical cystectomy for bladder cancer.. Journal of Clinical Oncology. 32(4_suppl). 295–295. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact